-
Product Insights
Net Present Value Model: Cevaretigene Ritoparvovec
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Cevaretigene Ritoparvovec Drug Details AAV-RPE65 is...
-
Product Insights
Net Present Value Model: AAV-AQP1
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model AAV-AQP1 Drug Details AAV-AQP1 is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – cevaretigene ritoparvovec
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry cevaretigene ritoparvovec Drug Details AAV-RPE65 is under development for the treatment of Leber congenital...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – botaretigene sparoparvovec
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry botaretigene sparoparvovec Drug Details AAV-RPGR is under development for the treatment of X-linked retinitis...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – entacingene turiparvovec
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry entacingene turiparvovec Drug Details AAV-CNGB3 is under development for the treatment of achromatopsia. It...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – aguracingene cadoparvovec
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry aguracingene cadoparvovec Drug Details AAV-CNGA3 is under development for the treatment of achromatopsia. The...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AAV-AQP1
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry AAV-AQP1 Drug Details AAV-AQP1 is under development for the treatment of xerostomia resulting from...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ARTI-02
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ARTI-02 Drug Details ARTI-02 is under development for the treatment of rheumatoid arthritis and...
-
Product Insights
Xerostomia Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The xerostomia clinical trial market research report provides an overview of the xerostomia clinical trials scenario. The report provides top-line data relating to the clinical trials on xerostomia. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.